Sermorelin vs. Ipamorelin: How Do the GH Peptides Compare?

By Astra Editorial Team

Published: 2026-09-15

Updated: 2026-09-15

If you’ve been researching growth hormone peptides, the sermorelin vs. ipamorelin question comes up fast, because these two are the go-to options in most wellness clinics. Both push your body to make more of its own growth hormone (GH). But they take different routes, carry different amounts of research, and differ a lot in whether you can even get them.

Sermorelin vs. ipamorelin at a glance

Quick answer: Sermorelin is a GHRH-based peptide with a long clinical history that you can still get through compounding. Ipamorelin is a more selective ghrelin-type peptide with a cleaner hormone profile, but it’s currently not available through compounding.

	Sermorelin	Ipamorelin
Peptide type	GHRH analog	Ghrelin mimetic (a GHRP-type secretagogue)
How it triggers GH	Works the GHRH receptor in the pituitary	Works the ghrelin receptor (GHSR)
Selectivity	Fairly clean; minor hormone shifts in one study	Very clean. No rise in cortisol, prolactin, or ACTH
Human research	Extensive; once an FDA-approved medicine (Geref)	Limited; strong lab data, never FDA-approved
Typical dosing	Nightly injection under the skin	Injection, often one to three times a day
Compoundable now?	Yes	No (in regulatory limbo)
Allowed in sport?	No	No

How sermorelin and ipamorelin work

Quick answer: Sermorelin copies GHRH and knocks on the pituitary’s GHRH receptor. Ipamorelin copies ghrelin and knocks on a different door, the ghrelin (GHS) receptor. Both end with the pituitary releasing more GH.

Sermorelin is built from the working end of growth hormone–releasing hormone (GHRH). So it speaks to the pituitary in a signal the gland already knows. Ipamorelin is different. It’s a small peptide that copies ghrelin, the “hunger hormone,” and grabs the ghrelin receptor to trigger a GH release.

Both leave your natural feedback loop in place, so neither floods the body with GH. Your own controls keep the peaks in a normal range.

Sermorelin vs ipamorelin: Which one is more selective?

Quick answer: Ipamorelin wins on selectivity. It raises GH without nudging cortisol, prolactin, or ACTH, even at high doses. Sermorelin is also fairly clean but showed small shifts in a few other hormones in one study.

Being selective is ipamorelin’s headline feature. When researchers first described it in 1998, they found it raised GH without touching cortisol, prolactin, or thyroid hormones. That held true even at very high doses. It’s a real edge over older ghrelin-type peptides like GHRP-6, which tend to raise stress hormones. 

Sermorelin is also well tolerated. One study noted small, brief rises in a couple of other hormones. In practice, both are clean, with ipamorelin holding a slight edge.

Sermorelin vs ipamorelin: Which has more research behind it?

Quick answer: Sermorelin. It spent years on the market as an approved medicine and has been studied in both children and adults, while ipamorelin’s evidence is mostly preclinical and it never earned FDA approval.

This is where sermorelin pulls ahead. Sermorelin was sold for years as a prescription drug. It was also tested in growth-hormone-deficient children and older adults, giving it a real human track record. Ipamorelin is backed by strong lab and animal work, plus some early human studies. 

But it stalled in testing and was never approved for any use. Neither peptide has large, long-term trials in healthy adults chasing anti-aging benefits. If a longer clinical history matters to you, sermorelin is the more proven pick.

Can you still get sermorelin and ipamorelin?

Quick answer: Right now, sermorelin is the one you can actually obtain. It’s legal to prescribe and compound, while ipamorelin was pulled from the compounding list in 2024 and its return is still undecided.

Sermorelin stays openly available through compounding pharmacies. It has held a friendly spot in the rules right through the recent peptide crackdowns. Ipamorelin is a different story. It was dropped from the compounding list in September 2024 after its nomination was withdrawn. A 2026 federal announcement signaled a plan to bring it back, but that decision is still pending. 

Until that’s settled, most providers cannot compound ipamorelin. So for most people, sermorelin is the realistic option. Astra offers compounded sermorelin but not ipamorelin.

Sermorelin vs ipamorelin: Which is better for you?

Quick answer: Ipamorelin edges ahead on selectivity, sermorelin on evidence and availability. Some protocols pair a GHRH peptide with a ghrelin-type peptide for a bigger GH pulse, but that’s a provider’s call.

For most people today, access settles it in sermorelin’s favor. Clinicians sometimes pair a GHRH-type peptide with a ghrelin-type one, because the two pathways can boost each other. That’s why sermorelin and ipamorelin — or ipamorelin with CJC-1295 — are often mentioned together. That kind of stack needs a doctor’s care. And it isn’t practical right now, while ipamorelin sits off the compounding list.

Frequently Asked Questions

References

• National Cancer Institute. Ipamorelin — NCI Drug Dictionary. National Institutes of Health. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ipamorelin
• Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561. https://pubmed.ncbi.nlm.nih.gov/9849822/
• Smith RG, Thorner MO. Growth hormone secretagogues as potential therapeutic agents to restore growth hormone secretion in older subjects to those observed in young adults. J Gerontol A Biol Sci Med Sci. 2023;78(Suppl 1):38–43. https://pubmed.ncbi.nlm.nih.gov/37325967/
• Sinha DK, Balasubramanian A, Tatem AJ, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020;9(Suppl 2):S149–S159. https://pmc.ncbi.nlm.nih.gov/articles/PMC7108996/
• Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307–308. https://pmc.ncbi.nlm.nih.gov/articles/PMC2699646/

Related Astra programs

• Sermorelin program
• See if you qualify

This article is for educational purposes only and does not constitute medical advice. Consult a licensed physician regarding any medical condition or treatment.